Foresite Capital Management Ii, Llc - Net Worth and Insider Trading

Foresite Capital Management Ii, Llc Net Worth

The estimated net worth of Foresite Capital Management Ii, Llc is at least $141 Million dollars as of 2024-05-14. Foresite Capital Management Ii, Llc is the 10% Owner of Aimmune Therapeutics Inc and owns about 4,087,900 shares of Aimmune Therapeutics Inc (AIMT) stock worth over $141 Million. Details can be seen in Foresite Capital Management Ii, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Foresite Capital Management Ii, Llc has not made any transactions after 2015-08-24 and currently still holds the listed stock(s).

Transaction Summary of Foresite Capital Management Ii, Llc

To

Foresite Capital Management Ii, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Foresite Capital Management Ii, Llc owns 3 companies in total, including 10x Genomics Inc (TXG) , Aerie Pharmaceuticals Inc (AERI) , and Aimmune Therapeutics Inc (AIMT) .

Click here to see the complete history of Foresite Capital Management Ii, Llc’s form 4 insider trades.

Insider Ownership Summary of Foresite Capital Management Ii, Llc

Ticker Comapny Transaction Date Type of Owner
TXG 10x Genomics Inc 2020-03-04 10 percent owner
AERI Aerie Pharmaceuticals Inc 2016-07-22 10 percent owner
AIMT Aimmune Therapeutics Inc 2016-08-18 10 percent owner

Foresite Capital Management Ii, Llc Latest Holdings Summary

Foresite Capital Management Ii, Llc currently owns a total of 1 stock. Foresite Capital Management Ii, Llc owns 4,087,900 shares of Aimmune Therapeutics Inc (AIMT) as of August 24, 2015, with a value of $141 Million.

Latest Holdings of Foresite Capital Management Ii, Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AIMT Aimmune Therapeutics Inc 2015-08-24 4,087,900 34.49 140,991,671

Holding Weightings of Foresite Capital Management Ii, Llc


Foresite Capital Management Ii, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Foresite Capital Management Ii, Llc has made a total of 0 transactions in Aimmune Therapeutics Inc (AIMT) over the past 5 years. The most-recent trade in Aimmune Therapeutics Inc is the acquisition of 25,485 shares on August 24, 2015, which cost Foresite Capital Management Ii, Llc around $500,780.

Insider Trading History of Foresite Capital Management Ii, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Foresite Capital Management Ii, Llc Trading Performance

GuruFocus tracks the stock performance after each of Foresite Capital Management Ii, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Foresite Capital Management Ii, Llc is -12.49%. GuruFocus also compares Foresite Capital Management Ii, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Foresite Capital Management Ii, Llc within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Foresite Capital Management Ii, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Foresite Capital Management Ii, Llc

Average Return

Average return per transaction

Outperforming Transactions

0 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 16.57
Relative Return to S&P 500(%) 18.49

Foresite Capital Management Ii, Llc Ownership Network

Ownership Network List of Foresite Capital Management Ii, Llc

No Data

Ownership Network Relation of Foresite Capital Management Ii, Llc


Foresite Capital Management Ii, Llc Owned Company Details

What does 10x Genomics Inc do?

Who are the key executives at 10x Genomics Inc?

Foresite Capital Management Ii, Llc is the 10 percent owner of 10x Genomics Inc. Other key executives at 10x Genomics Inc include director & 10 percent owner & Chief Executive Officer Serge Saxonov , director & See Remarks Benjamin J. Hindson , and Chief Financial Officer Justin J. Mcanear .

10x Genomics Inc (TXG) Insider Trades Summary

Over the past 18 months, Foresite Capital Management Ii, Llc made no insider transaction in 10x Genomics Inc (TXG). Other recent insider transactions involving 10x Genomics Inc (TXG) include a net sale of 90,937 shares made by Serge Saxonov , a net sale of 36,912 shares made by Benjamin J. Hindson , and a net sale of 9,758 shares made by Justin J. Mcanear .

In summary, during the past 3 months, insiders sold 11,959 shares of 10x Genomics Inc (TXG) in total and bought 0 shares, with a net sale of 11,959 shares. During the past 18 months, 208,804 shares of 10x Genomics Inc (TXG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 208,804 shares.

10x Genomics Inc (TXG)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

10x Genomics Inc Insider Transactions

No Available Data

Foresite Capital Management Ii, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Foresite Capital Management Ii, Llc. You might contact Foresite Capital Management Ii, Llc via mailing address: 900 Larkspur Landing Circle, Suite 150, Larkspur Ca 94939.

Discussions on Foresite Capital Management Ii, Llc

No discussions yet.